Medera (www.medera.bio) is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with next-generation gene and cell-based approaches. Medera operates via the two preclinical and clinical units: 1) Novoheart capitalizes on the world's first "mini-Heart"Technology for revolutionary disease modelling and drug discovery, uniquely enabling the modelling of human-specific diseases and discovery of therapeutic candidates free from species-specific differences in accordance to FDA Modernisation Act 2.0. 2) Leveraging Novoheart's human-based discovery and validation platforms, Sardocor has IND clearances from the FDA for three ongoing AAV-based cardiac gene therapy clinical trials for Heart Failure with Reduced Ejection Fraction (HFrEF), Heart Failure with Preserved Ejection Fraction (HFpEF) with Fast Track Designation, and Duchenne Muscular Dystrophy-induced Cardiomyopathy (DMD-CM) with Orphan Drug Designation.